EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Cognitive function, quality of life, and survival outcomes in patients with lower grade gliomas treated with proton radiation therapy: A phase II study

Jason M Slater iD, Nora K Horick, Lisa B Nachtigall, Michael W Parsons, Nicholas A Tritos, Alexander T Faje, Jorg Dietrich, Barbara Fullerton, Janet C Sherman, William T Curry, Isabel C Arrillaga-Romany, Daniel P Cahill iD und 6 weitere

Neuro-Oncology · 01.05.2026 · 28 (5) · 1266-1276

DOI: 10.1093/neuonc/noag008 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Neuro-Oncology, online erschienen am 25.01.2026. Verfasst von Jason M Slater und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Medicine, Loma Linda University Medical Center, Loma Linda, CA, USA. Hauptthemen laut MEDLINE: Proton Therapy, Quality of Life, Brain Neoplasms, Glioma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Cancer Institute research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lower grade gliomas (LGGs) typically affect younger adults and are associated with long-term survival. Treatment-related toxicities, especially neurocognitive and neuroendocrine effects, are a concern. Proton therapy may reduce these risks by minimizing radiation exposure to healthy brain tissue. This study evaluates the safety and efficacy of proton therapy in LGG patients, focusing on neurocognitive, neuroendocrine, and quality-of-life (QOL) outcomes.

Methods

This single-institution, prospective phase 2 trial enrolled 60 patients with WHO grade 1-2 gliomas or IDH-mutant grade 3 gliomas. Proton therapy was delivered at 54 Gy(RBE) or 59.4 Gy(RBE) by tumor grade. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), neurocognitive and neuroendocrine function, and QOL. Neurocognitive testing occurred at baseline and biennially. Quality-of-life was assessed using the FACT-Brain questionnaire. Toxicities were graded per CTCAE v4.0.

Results

With a median follow-up of 7.0 years, 5-year PFS and OS were 79.1% and 85.6%, respectively. Progression-free survival was highest in IDH-mutant, 1p/19q co-deleted gliomas (100%) and lowest in IDH-wildtype tumors (62.5%). New neurocognitive deficits occurred in 26% of patients at 5 years. Neuroendocrine dysfunction occurred in 5.3%, with only one case attributed to radiation. Quality-of-life declined transiently at 6 months, with 15% showing a clinically meaningful decline at 5 years. No late grade 3 toxicities were observed; one case of grade 4 radionecrosis occurred.

Conclusions

Proton therapy for LGG can offer effective disease control with modest long-term toxicity. These findings support its use as a standard radiation modality and highlight the need for comparative trials with photon therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton TherapyQuality of LifeBrain NeoplasmsGliomaCognitionHumansFemaleMiddle AgedMaleAdultProspective StudiesFollow-Up StudiesAgedSurvival RateNeoplasm GradingPrognosisYoung Adult

Stichwörter der Autor:innen

cognitive functionlower grade gliomaneuroendocrineproton therapyquality of life

Autor:innen und Institutionen

  • Department of Radiation Medicine, Loma Linda University Medical Center, Loma Linda, CA, USA.
  • Department of Radiation Oncology, Massachusetts General Hospital/Mass General Brigham, Boston, MA, USA.
  • Division of Biostatistics, Department of Medicine, Massachusetts General Hospital/Mass General Brigham, Boston, MA, USA.
  • Division of Endocrinology, Department of Medicine, Massachusetts General Hospital/Mass General Brigham, Boston, MA, USA.
  • Harvard Medical School, Harvard University, Boston, MA, USA.
  • Department of Psychiatry, Massachusetts General Hospital/Mass General Brigham, Boston, MA, USA.

ORCID-Profile: Jason M Slater, Daniel P Cahill, Helen A Shih

Förderung

  • National Cancer Institute research

Zitieren

APA

Slater, J. M., Horick, N. K., Nachtigall, L. B., Parsons, M. W., Tritos, N. A., Faje, A. T., Dietrich, J., Fullerton, B., Sherman, J. C., Curry, W. T., Arrillaga-Romany, I. C., Cahill, D. P., Nahed, B. V., Wang, I. S., Botticello, T. M., Oh, K. S., Yeap, B. Y., & Shih, H. A. (2026). Cognitive function, quality of life, and survival outcomes in patients with lower grade gliomas treated with proton radiation therapy: A phase II study. Neuro-Oncology, 28(5), 1266-1276. https://doi.org/10.1093/neuonc/noag008

Vancouver

Slater JM, Horick NK, Nachtigall LB, Parsons MW, Tritos NA, Faje AT, et al. Cognitive function, quality of life, and survival outcomes in patients with lower grade gliomas treated with proton radiation therapy: A phase II study. Neuro-Oncology. 2026;28(5):1266-1276. doi:10.1093/neuonc/noag008

BibTeX
@article{Slater2026,
  author = {Slater, Jason M and Horick, Nora K and Nachtigall, Lisa B and Parsons, Michael W and Tritos, Nicholas A and Faje, Alexander T and Dietrich, Jorg and Fullerton, Barbara and Sherman, Janet C and Curry, William T and Arrillaga-Romany, Isabel C and Cahill, Daniel P and Nahed, Brian V and Wang, Irene S and Botticello, Thomas M and Oh, Kevin S and Yeap, Beow Y and Shih, Helen A},
  title = {Cognitive function, quality of life, and survival outcomes in patients with lower grade gliomas treated with proton radiation therapy: A phase II study},
  journal = {Neuro-Oncology},
  year = {2026},
  volume = {28},
  number = {5},
  pages = {1266--1276},
  doi = {10.1093/neuonc/noag008}
}
Kostenlos starten →